Activity of decitabine combined with all-trans retinoic acid in oligoblastic AML: Results from a randomized 2x2 phase II trial (DECIDER)
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
Haematologica. - 108, 8 (2023) , 2244-2248, ISSN: 1592-8721
- Event
-
Veröffentlichung
- (where)
-
Freiburg
- (who)
-
Universität
- (when)
-
2023
- Creator
- DOI
-
10.3324/haematol.2022.282258
- URN
-
urn:nbn:de:bsz:25-freidok-2330846
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:58 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
Time of origin
- 2023
Other Objects (12)
Impact of TP53 mutation status in elderly AML patients when adding all‐trans retinoic acid or valproic acid to decitabine
Statistical models for complex data in clinical and epidemiological research
Design aspects of COVID‐19 treatment trials: Improving probability and time of favorable events
Long-term decitabine/retinoic acid maintenance treatment in an elderly sAML patient with high-risk genetics
Long-term decitabine/retinoic acid maintenance treatment in an elderly sAML patient with high-risk genetics
Plasma cell leukemia: another piece of the puzzle
Identifikation neuer Zielgene der Helix-Loop-Helix-Proteine der ID-Familie
S125: 10-day decitabine vs. conventional chemotherapy (“3 + 7”) followed by allografting (HSCT) in AML patients ≥60 years: a randomized phase III study of the EORTC Leukemia Group, GIMEMA, CELG, and GMDS-SG
Statistical models for complex data in clinical and epidemiological research
Personen mit Migrationshintergrund in der NAKO Gesundheitsstudie – soziodemografische Merkmale und Vergleiche mit der autochthonen deutschen Bevölkerung : = Persons with migration background in the German National Cohort (NAKO) - sociodemographic characteristics and comparisons with the German autochthonous population
Design aspects of COVID‐19 treatment trials: Improving probability and time of favorable events
Relapsed/refractory diffuse large b-cell lymphoma: is there still a role for autologous stem cell transplantation in the CAR T-cell era?
Impact of TP53 mutation status in elderly AML patients when adding all‐trans retinoic acid or valproic acid to decitabine
Statistical models for complex data in clinical and epidemiological research
Design aspects of COVID‐19 treatment trials: Improving probability and time of favorable events
Long-term decitabine/retinoic acid maintenance treatment in an elderly sAML patient with high-risk genetics
Long-term decitabine/retinoic acid maintenance treatment in an elderly sAML patient with high-risk genetics
Plasma cell leukemia: another piece of the puzzle
Identifikation neuer Zielgene der Helix-Loop-Helix-Proteine der ID-Familie
S125: 10-day decitabine vs. conventional chemotherapy (“3 + 7”) followed by allografting (HSCT) in AML patients ≥60 years: a randomized phase III study of the EORTC Leukemia Group, GIMEMA, CELG, and GMDS-SG
Statistical models for complex data in clinical and epidemiological research
Personen mit Migrationshintergrund in der NAKO Gesundheitsstudie – soziodemografische Merkmale und Vergleiche mit der autochthonen deutschen Bevölkerung : = Persons with migration background in the German National Cohort (NAKO) - sociodemographic characteristics and comparisons with the German autochthonous population
Design aspects of COVID‐19 treatment trials: Improving probability and time of favorable events
Relapsed/refractory diffuse large b-cell lymphoma: is there still a role for autologous stem cell transplantation in the CAR T-cell era?
Impact of TP53 mutation status in elderly AML patients when adding all‐trans retinoic acid or valproic acid to decitabine
Statistical models for complex data in clinical and epidemiological research
Design aspects of COVID‐19 treatment trials: Improving probability and time of favorable events
Long-term decitabine/retinoic acid maintenance treatment in an elderly sAML patient with high-risk genetics
Long-term decitabine/retinoic acid maintenance treatment in an elderly sAML patient with high-risk genetics
Plasma cell leukemia: another piece of the puzzle
Identifikation neuer Zielgene der Helix-Loop-Helix-Proteine der ID-Familie
S125: 10-day decitabine vs. conventional chemotherapy (“3 + 7”) followed by allografting (HSCT) in AML patients ≥60 years: a randomized phase III study of the EORTC Leukemia Group, GIMEMA, CELG, and GMDS-SG
Statistical models for complex data in clinical and epidemiological research
Personen mit Migrationshintergrund in der NAKO Gesundheitsstudie – soziodemografische Merkmale und Vergleiche mit der autochthonen deutschen Bevölkerung : = Persons with migration background in the German National Cohort (NAKO) - sociodemographic characteristics and comparisons with the German autochthonous population
Design aspects of COVID‐19 treatment trials: Improving probability and time of favorable events